Biotech

All Articles

Ideaya bags possibility on Biocytogen bispecific ADC in $400M package

.Ideaya Biosciences is actually wagering $400 million in biobucks that a bispecific antibody-drug co...

Takeda takes $140M loss on failed epilepsy drug, touts FDA operate

.Our company presently recognize that Takeda is wishing to discover a road to the FDA for epilepsy m...

VBI Injections declare bankruptcy, finds asset sale

.Immunology biotech VBI Vaccines is diverting hazardously near the point of no return, with plans to...

Celldex anti-cKIT antibody decrease hives in one more stage 2 study

.It is actually hard to muscular tissue in on a room as affordable as immunology, yet Celldex Rehabs...

Boehringer offers up to $1.3 B for gate inhibitor biotech

.Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapeutics as well as a preclinical...

Ventyx's last resort for inflamed med sides in Crohn's failure

.Ventyx Biosciences' Crohn's condition medication carried out not aid clients obtain remission in a ...

Cognition's period 2 SHINE records tarnish Alzheimer's possibility

.Cognition Rehabs' stage 2 luster trial has taken several of the luster off the Alzheimer's health c...

BMS axes bispecific months after filing to run period 3 test

.Bristol Myers Squibb has possessed a whiplash change of mind on its BCMA bispecific T-cell engager,...

Charles Baum takes over Terremoto as CEO

.Charles Baum, M.D., Ph.D., who looked after Mirati Therapies' $ 5.8 billion purchase to Bristol Mye...

Asarina to close after attempts to partner Tourette's drug fail

.After communicating to greater than 200 business to partner a Tourette disorder therapy that reveal...